On the issue of efficacy and safety of the long-term use of darolutamide in combination therapy in patients with non-metastatic castration-resistant prostate cancer (on the example of one clinical case)

Background and aim. The development of non-metastatic castration-resistant prostate cancer (nmCRPC) in patients is usually associated with high risk of the disease progression to the metastatic castration-resistant disease. A number of studies have confirmed the feasibility of using novel antiandrogens (specifically darolutamide) to improve metastasis-free survival and overall survival in this category of patients. However, scientific data on the long-term follow-up of patients receiving darolutamide under conditions of real clinical practice are actually missing and are limited to the periods of follow-up within the framework of clinical trials. That is why the case reports from real clinical practice, in which the data on the health of patients receiving darolutamide for a long time due to nmCRPC are provided, are of special interest. Methods. The paper reports a clinical case of using darolutamide for more than seven years in a patient with nmCRPC at high risk of the disease progression. Results and conclusions. The case report provided showing the efficacy and safety profile of the long-term darolutamide therapy and the case report analysis will help optimize treatment tactics selection in other such situations.